title: Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
abstract: BACKGROUND
  To evaluate the clinicopathologic and demographic characteristics of triple-negative breast cancer (TNBC) patients and to determine differences from non-triple-negative cases.
  
  
  METHODS
  A detailed review of the medical records of 882 breast cancer (BC) patients was conducted to obtain information regarding age, menopausal status, height and weight at the time of diagnosis, presence of diabetes or hypertension, and pathologic characteristics of the tumor (tumor size, lymph node status, histologic grade, ER status, PR status, HER2 status, p53 mutation). Body mass index (BMI) was calculated and a value of ≥30 was considered as indicative of obesity.
  
  
  RESULTS
  14.9% (n=132) of the patients had TNBC. There was no difference among the patients in terms of median age, comorbid conditions and menopausal status. The proportion of medullary, tubular and mucinous carcinomas was significantly higher (15.9%) in the triple-negative (TN) group, while invasive lobular histology was more frequent (8.2%) among non-triple negative (NTN) cases (p<0.001). Grade 3 (G3) tumors were more frequent in the triple-negative group (p<0.001). The rate of p53 mutation was 44.3% in TN tumors versus 28.2% in the NTN group (p<0.001). The two groups were similar in terms of LN metastasis. In the NTN group, the rate of patients with BMI ≥30 was 53% among postmenopausal patients, while it was 36% among premenopausal women, and the difference was statistically significant (p<0.001). No significant difference was observed in terms of BMI between postmenopausal and premenopausal patients in the TN group (p=0.08).
  
  
  CONCLUSIONS
  TNBC rates and clinicopathologic characteristics of the Turkish patient population were consistent with the data from Europe and America. However, no relationship between obesity and TNBC was observed in our study. The association between TNBC and obesity needs to be evaluated in a larger patient population.
authors.affiliation: Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University Medical Faculty, Turkey E-mail : demir.lutfiye77@gmail.com.
authors.forename: Isil
authors.initials: I
authors.lastname: Somali
authors.forename: Bahar Yakut
authors.initials: BY
authors.lastname: Ustaoglu
authors.forename: Mustafa Oktay
authors.initials: MO
authors.lastname: Tarhan
authors.forename: Seyran Ceri
authors.initials: SC
authors.lastname: Yigit
authors.forename: Lutfiye
authors.initials: L
authors.lastname: Demir
authors.forename: Hulya
authors.initials: H
authors.lastname: Ellidokuz
authors.forename: Cigdem
authors.initials: C
authors.lastname: Erten
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000378:metabolism / Q000556:secondary*; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000378:metabolism / Q000556:secondary*; D003710:Demography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D017697:Premenopause; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D064726:Triple Negative Breast Neoplasms / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology*; D014421:Turkey / Q000453:epidemiology; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone